Checkpoint Therapeutics Announces Positive Interim Results from Registration-Enabling Trial of Cosibelimab in Metastatic Cutaneous Squamous Cell Carcinoma

~ 51.4% objective response rate and 13.5% complete response rate in half the planned pivotal cohort ~ Interim results presented at ESMO Virtual Congress 2020 ~ On track to report full top-line results in mid-2021 ~ Potentially favorable safety profile compared to anti-PD-1 therapies ~ Market-disruptive pricing planned in $25 billion PD-(L)1 market

Daniel Carlson

September 17, 2020

Thank you for visiting Tailwinds Research. We are pleased to offer free research on select small and micro cap companies. It is free to join and we hope you’ll take the time to do so.

To create an account please click on this link.

If you already have an account, please log in here.

LEAVE A REPLY Cancel reply

DFC Advisory Services LLC (dba TW Research Group) is an investment adviser. We are also compensated for publishing information on certain companies. Information presented is for educational purposes only and does not intend to make an offer or solicitation for the sale or purchase of any specific securities, investments, or investment strategies. Investments involve risk and unless otherwise stated, are not guaranteed. Be sure to first consult with a qualified financial adviser and/or tax professional before implementing any strategy discussed herein. Past performance is not indicative of future performance.